In HFD-induced NAFLD mice, treatment with a dual GLP-1/glucagon co-agonist for 40 weeks prevented body weight gain, glucose intolerance and insulin resistance, while it decreased circulating and hepatic lipid content. The gene discussed is GCG; the disease is Insulin resistance.